These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 20810399)
41. Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). Sinclair A; Appel G; Dooley MA; Ginzler E; Isenberg D; Jayne D; Wofsy D; Solomons N Lupus; 2007; 16(12):972-80. PubMed ID: 18042591 [TBL] [Abstract][Full Text] [Related]
42. Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Gaubitz M; Schorat A; Schotte H; Kern P; Domschke W Lupus; 1999; 8(9):731-6. PubMed ID: 10602445 [TBL] [Abstract][Full Text] [Related]
43. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Dooley MA; Houssiau F; Aranow C; D'Cruz DP; Askanase A; Roth DA; Zhong ZJ; Cooper S; Freimuth WW; Ginzler EM; Lupus; 2013 Jan; 22(1):63-72. PubMed ID: 23263865 [TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Rovin BH; Furie R; Latinis K; Looney RJ; Fervenza FC; Sanchez-Guerrero J; Maciuca R; Zhang D; Garg JP; Brunetta P; Appel G; Arthritis Rheum; 2012 Apr; 64(4):1215-26. PubMed ID: 22231479 [TBL] [Abstract][Full Text] [Related]
45. Serum immunoglobulin G level in patients with lupus nephritis and the effect of treatment with corticosteroids and mycophenolate mofetil. Yap DY; Yung S; Ma MK; Mok MM; Kwan LP; Chan GC; Chan TM Lupus; 2014 Jun; 23(7):678-83. PubMed ID: 24554708 [TBL] [Abstract][Full Text] [Related]
46. Mycophenolate Mofetil in Nonrenal Manifestations of Systemic Lupus Erythematosus: An Observational Cohort Study. Tselios K; Gladman DD; Su J; Urowitz MB J Rheumatol; 2016 Mar; 43(3):552-8. PubMed ID: 26773121 [TBL] [Abstract][Full Text] [Related]
47. Mycophenolate mofetil in systemic lupus erythematosus: results from a retrospective study in a large monocentric cohort and review of the literature. Conti F; Ceccarelli F; Perricone C; Massaro L; Cipriano E; Pacucci VA; Truglia S; Miranda F; Morello F; Alessandri C; Spinelli FR; Valesini G Immunol Res; 2014 Dec; 60(2-3):270-6. PubMed ID: 25468307 [TBL] [Abstract][Full Text] [Related]
48. Mycophenolate mofetil in the treatment of uveitis in children. Doycheva D; Deuter C; Stuebiger N; Biester S; Zierhut M Br J Ophthalmol; 2007 Feb; 91(2):180-4. PubMed ID: 16825275 [TBL] [Abstract][Full Text] [Related]
49. Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study. Orth T; Peters M; Schlaak JF; Krummenauer F; Wanitschke R; Mayet WJ; Galle PR; Neurath MF Am J Gastroenterol; 2000 May; 95(5):1201-7. PubMed ID: 10811328 [TBL] [Abstract][Full Text] [Related]
50. Open label randomized controlled trial assessing the efficacy of mycophenolate sodium against other conventional immunosuppressive agents in active systemic lupus erythematosus patients without renal involvement. Yahya F; Jasmin R; Ng CT; Cheah TE; Sockalingam S Int J Rheum Dis; 2013 Dec; 16(6):724-30. PubMed ID: 24119227 [TBL] [Abstract][Full Text] [Related]
51. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Hu W; Liu Z; Chen H; Tang Z; Wang Q; Shen K; Li L Chin Med J (Engl); 2002 May; 115(5):705-9. PubMed ID: 12133539 [TBL] [Abstract][Full Text] [Related]
52. Does mycophenolate mofetil prevent extra-renal flares in systemic lupus erythematosus? Results from an observational study of patients in a single practice treated for up to 5 years. Posalski JD; Ishimori Ml; Wallace DJ; Weisman MH Lupus; 2009 May; 18(6):516-21. PubMed ID: 19395453 [TBL] [Abstract][Full Text] [Related]
53. [Revision of the recommendations of the Commission on Pharmacotherapy of the German Society for Rheumatology. Comment on the use of mycophenolic acid for systemic lupus erythematosus]. Fischer-Betz R; Hiepe F; Z Rheumatol; 2007 Feb; 66(1):78-82. PubMed ID: 17216418 [TBL] [Abstract][Full Text] [Related]
54. Induction therapy for active lupus nephritis: mycophenolate mofetil versus cyclophosphamide. Burchardi C; Schlöndorff D Nat Clin Pract Nephrol; 2006 Jun; 2(6):314-5. PubMed ID: 16932452 [No Abstract] [Full Text] [Related]
55. Mycophenolate mofetil therapy for children with lupus nephritis refractory to both intravenous cyclosphosphamide and cyclosporine. Fu YF; Liu GL Clin Nephrol; 2001 Apr; 55(4):318-21. PubMed ID: 11334319 [TBL] [Abstract][Full Text] [Related]
56. Treatment of pulmonary hemorrhage in childhood systemic lupus erythematosus with mycophenolate mofetil. Samad AS; Lindsley CB South Med J; 2003 Jul; 96(7):705-7. PubMed ID: 12940327 [TBL] [Abstract][Full Text] [Related]
57. Induction therapy for pediatric focal proliferative lupus nephritis: cyclophosphamide versus mycophenolate mofetil. Lau KK; Ault BH; Jones DP; Butani L J Pediatr Health Care; 2008; 22(5):282-8. PubMed ID: 18761229 [TBL] [Abstract][Full Text] [Related]
59. [Mycophenolate mofetil in the treatment of lupus nephritis, in patients with failure, intolerance or relapses after treatment with steroids and cyclophosphamide]. Suría S; Checa MD Nefrologia; 2007; 27(4):459-65. PubMed ID: 17944583 [TBL] [Abstract][Full Text] [Related]
60. Real-World Experience of Safety of Mycophenolate Mofetil in 119 Japanese Patients with Systemic Lupus Erythematosus: A Retrospective Single-Center Study. Abe Y; Tada K; Yamaji K; Tamura N Biomed Res Int; 2021; 2021():8630596. PubMed ID: 33564682 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]